A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together ...
Jan 8, 2013
0
0
A new case report was published in Oncoscience on September 20, 2023, titled, "Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma."
Jan 15, 2024
0
0
In patients with soft tissue sarcoma, the concomitant use of gastric acid suppressant (GAS) therapy and the anticancer therapeutic pazopanib (Votrient) was associated with significantly reduced progression-free survival and ...
Feb 14, 2019
0
0
Severe illnesses sometimes require treatment regimens carrying grave risks, including organ failure. Now, a non-invasive technique developed at A*STAR could help predict patient vulnerability to potentially toxic drugs.
May 31, 2017
0
0
A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, ...
Mar 13, 2014
0
0
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
Aug 21, 2013
0
0
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with ...
Jun 3, 2013
0
1
A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.
Jun 1, 2013
0
1
(HealthDay) -- Long-term medication side effects such as fatigue can be key for patients deciding which cancer drug to take, new research suggests.
Jun 2, 2012
0
0
Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting ...
Jun 1, 2012
0
0
